Aprogen Q1 2026: Continued Losses and Capital Reduction Plan

Consolidated revenue: 36.3B KRW, operating loss: 20.6B KRW, net loss: 28.1B KRW (parent -17.9B KRW)
Biopharmaceutical segment: zero revenue, operating loss 14.3B KRW (R&D intensive)
Pharmaceuticals segment revenue: 14.5B KRW, hardfacing: 8.0B KRW, semiconductor parts: 7.2B KRW
R&D expenses: 5.8B KRW (16.1% of revenue)
Biosimilar AP063 (Herceptin): pursuing EMA Phase 3 waiver strategy
Consolidated debt ratio: 61.7%, total equity: 430.8B KRW
Post-reporting: 15:1 stock consolidation (Aprogen, Aprogen Biologics, etc.)
Pledge of major shareholder shares and changes in borrowings